Neuroscience Markers

Advancements in biomarker research have enabled the detection of key pathological proteins, including amyloid-beta (Aβ), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), in blood and cerebrospinal fluid (CSF). 

Take Alzheimer’s disease (AD) as an example: one of the most significant breakthroughs in AD diagnostics in recent years has been the development of blood-based biomarkers, with some assays demonstrating high diagnostic accuracy. This advancement has made the biological diagnosis of AD—which previously required positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis—more widely accessible. 

Similarly, efforts to slow the progression of Parkinson’s disease (PD) are advancing through the integration of sensitive biomarkers, enabling earlier detection and more effective disease management. Additionally, in the context of TBI, the use of imaging and fluid biomarkers to predict outcomes and identify high-risk patients in the acute phase is steadily increasing. 

The development of fluid biomarker assays would facilitate large-scale screening in a cost-effective manner, enhancing both early intervention and long-term monitoring. Hytest high-quality antibodies and antigens are specifically designed to support the detection of key biomarkers such as Aβ, NfL, and GFAP, among others, contributing to the advancement of fluid-based diagnostic assays for neurodegenerative diseases and TBI.